We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Igraine plc | AQSE:KING | Aquis Stock Exchange | Ordinary Share | GB00BM9CKV18 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.275 | 0.10 | 0.30 | 0.275 | 0.20 | 0.275 | 0.00 | 15:29:32 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMKING 18 August 2021 THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014, AS AMENDED ("MAR"). ON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE ("RIS"), THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN. Igraine plc ("Igraine" or the "Company") ARCADIA trial final report date announced Igraine plc ("the Company") notes the announcement on August 17, 2021 by Excalibur Medicines Limited, a subsidiary of Excalibur Healthcare Services Ltd - www.excaliburhealth.co.uk/news. Igraine is pleased to advise that the Clinical Team will report on the ARCADIA trial on September 6, 2021. Excalibur Medicines Ltd ("EML") has secured exclusive rights to and owns the patents on a drug, AZD1656, which is being developed as a potential therapeutic for people with diabetes suffering from COVID-19. The ARCADIA trial which took place across 31 sites was completed in July this year. The research project was arranged and structured by Professor Sir Chris Evans, Chairman and CEO of Excalibur Healthcare Services, through its subsidiary, Excalibur Medicines Ltd. Sir Chris worked closely with Professor John Martin and his team at St George Street, a UK-based biomedical research charity, which secured the initial project and permission to run the trial from AstraZeneca. Igraine plc secured a 2% Equity Interest in, Excalibur Medicines Ltd ("EML"), consistent with the terms of the co-investment agreement entered with Excalibur Healthcare Services. The Directors of the Company, who have issued this RIS announcement after due and careful enquiry, accept responsibility for its content. Enquiries Company: Martin Walton (Executive Director) Steve Winfield (Executive Director) info@igraineplc.com Office Line: +44 (0) 20 3778 0755 AQSE Growth Market Corporate Adviser Peterhouse Capital Limited Guy Miller / Mark Anwyl Tel: +44 (0) 207 469 0930 Media inquiries: Ramsay Smith, Media House International ramsay@mediahouse.co.uk: +44 (0) 7788414856 END
(END) Dow Jones Newswires
August 18, 2021 02:00 ET (06:00 GMT)
1 Year Igraine Chart |
1 Month Igraine Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions